Adjunctive taurine in first-episode psychosis: A phase 2, double-blind, randomized, placebo-controlled study

Abstract

Objective: Taurine is an inhibitory neuromodulatory amino acid in the central nervous system that activates the GABA-and glycine-insensitive chloride channel and inhibits the N-methyl-d-Aspartate receptor. It also functions as a neuroprotective agent and has a role in neural development and neurogenesis. The aim of this study was to determine the efficacy of adjunctive taurine in improving symptomatology and cognition among patients with a DSM-IV first-episode psychotic disorder. Methods: 121 patients with first-episode psychosis, aged 18-25 years, attending early intervention services consented to participate in this randomized, double-blind, placebo-controlled trial conducted from January ..